Is CRISPR Therapeutics (CRSP) Undervalued As Its Shares Trade Well Below Fair Value?

Recent Trading Context For CRISPR Therapeutics Stock

CRISPR Therapeutics (NasdaqGM:CRSP) has been trading with mixed short term moves, rising about 2.5% over the past day while declining around 4.6% over the past week and 11% over the past month.

See our latest analysis for CRISPR Therapeutics.

At a share price of $48.15, CRISPR Therapeutics has seen short term share price pressure, with the 30 day share price return down 10.98% and the year to date share price return down 10.45%, alongside a 1 year total shareholder return that is down 26.97% and weaker 3 and 5 year total shareholder returns. This suggests that recent volatility is part of a longer period of reassessment of the company’s risk and growth profile.

If you are weighing CRISPR Therapeutics against other opportunities in the sector, this is a useful moment to scan for 39 healthcare AI stocks.

CRISPR Therapeutics now trades well below both analyst price targets and one intrinsic value estimate. The real focus is where fair value sits within that spread and how much of the recent share price weakness it already reflects.

Preferred Multiple of 2.6x Price-to-Book: Is It Justified?

For CRISPR Therapeutics, the clearest snapshot of how the market is pricing the stock relative to its balance sheet is the P/B ratio of 2.6x.

P/B compares the share price to the company’s net assets, so at 2.6x you are paying a little over two and a half times CRISPR Therapeutics' book value per share. That figure sits below the peer average of 9.9x, which points to a lower valuation being placed on the company’s asset base compared with similar companies.

Against the wider US biotechs industry, however, CRISPR Therapeutics screens as relatively expensive because its 2.6x P/B lines up with the industry average of 2.6x rather than sitting at a discount. The market is therefore pricing the stock broadly in line with sector norms, even while it trades below one intrinsic value estimate and below analyst price targets.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 2.6x (ABOUT RIGHT)

However, CRISPR Therapeutics still carries clear risks, including a reported net loss of $568.534 million and reliance on a relatively narrow set of high stakes programs.

Find out about the key risks to this CRISPR Therapeutics narrative.

Another View: SWS DCF Model Versus The Market Price

While the P/B ratio suggests CRISPR Therapeutics trades roughly in line with the broader biotechs group, the SWS DCF model points to a very different picture. With a fair value estimate of $222.25 versus a $48.15 share price, the stock screens as deeply undervalued on this measure. The real question is whether the long term cash flow assumptions behind that gap feel realistic to you.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given this mix of pressure and potential around CRISPR Therapeutics, it may be useful to review the available data and decide where you stand, starting with the 2 key rewards and 2 important warning signs.

Looking For More Investment Ideas Beyond CRISPR Therapeutics?

If CRISPR Therapeutics has sharpened your thinking, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh stock ideas that fit your style.

• Target stability first by checking companies highlighted in the 81 resilient stocks with low risk scores that aim to keep risk scores in a more comfortable zone for cautious investors.
• Hunt for value by reviewing the screener containing 20 high quality undiscovered gems and spot lesser known businesses with fundamentals that might not yet be fully reflected in their share prices.
• Strengthen your core holdings by focusing on the solid balance sheet and fundamentals stocks screener (48 results) to see companies that pair financial resilience with underlying fundamental support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com